Leading pharmaceutical manufacturer, Aesica, has enhanced its presence in the US through the appointment of a new Business Development Director for the West Coast and opening of a new site in San Diego.
Gerard Scarlato will head up the new operation and focus on increasing awareness of Aesica and its unique service provision along the West Coast whilst supporting current activity across the Eastern states.
After graduating with a PhD Gerard has worked in Japan, Canada, Europe and various parts of the US, initially on the research side of pharmaceutical drug development before making the transition to business development 11 years ago.
Speaking of his appointment, Gerard said: “It’s an exciting time to be joining Aesica, a company which has gone from strength to strength since its formation in 2004. I aim to build on the foundations established by the team in New York and further raise awareness of the company here in San Diego and across the West Coast. With the support of Aesica’s senior management team I plan to secure new streams of business, identify routes for further expansion and work more closely with emerging biotechnology and specialty pharma companies.
“It is Aesica’s vision to become the world’s leading supplier of APIs and formulated products and enhancing the company’s presence in the US is a significant factor in ensuring this vision becomes a reality.”
Aesica Pharmaceuticals has also recently announced (29 June) that it has successfully acquired leading research and development company R5. R5 is Aesica’s third UK acquisition since 2006 and will complement its existing formulations capability and enable it to significantly consolidate and enhance its portfolio of pharmaceutical and biotechnology clients.
Aesica is one of the UK’s fastest growing companies with an annual turnover in the region of £100 million and is currently undergoing a period of significant expansion both in the UK and across America, where it has also relocated its East Coast operation to New York.
Aesica supplies Active Pharmaceutical Ingredients, Formulations and Development Services to a host of the world’s leading medical and pharmaceutical companies and emerging biotechnology organisations.
Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within the company enables it to provide primary and secondary contract manufacturing services to the highest possible standards. It is this all-encompassing offer and its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
Aesica was founded in 2004 and has since more than trebled in size, from having a single API site in the North East of England to being a significant global player with four API and Formulations development and manufacturing sites in the UK, global offices in New York, San Diego and Shanghai and an international customer base.